Spots Global Cancer Trial Database for relapsed neuroblastoma
Every month we try and update this database with for relapsed neuroblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma | NCT05650749 | Refractory Neur... Relapsed Neurob... High-risk Neuro... | GPC2 CAR T cell... | 1 Year - | Children's Hospital of Philadelphia | |
| DNA Vaccination Against Neuroblastoma | NCT04049864 | Relapsed Neurob... | DNA vaccine Salmonella oral... Lenalidomide | 1 Year - 20 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | NCT04023331 | Neuroblastoma Relapsed Neurob... Refractory Neur... | 67Cu-SARTATE 64Cu-SARTATE | - | Clarity Pharmaceuticals Ltd | |
| Rapid Administration Pilot for Infusing Dinutuximab | NCT05421897 | Neuroblastoma | Dinutuximab wit... | 1 Year - | Children's Hospital Los Angeles | |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | NCT04211675 | Relapsed Neurob... Refractory Neur... | Natural Killer ... Temozolomide Irinotecan Dinutuximab Sargramostim | - 29 Years | Nationwide Children's Hospital | |
| Parental Decision-Making for Children With Relapsed Neuroblastoma | NCT02282735 | Relapsed Neurob... | 18 Years - | Dana-Farber Cancer Institute | ||
| Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | NCT01059071 | Neuroblastoma | DFMO Etoposide | - | Milton S. Hershey Medical Center | |
| MIBG for Refractory Neuroblastoma and Pheochromocytoma | NCT01850888 | Relapsed Neurob... Metastatic Pheo... | 131 I-Metaiodob... Potassium iodid... G-CSF hematopoietic s... | 1 Year - | Masonic Cancer Center, University of Minnesota | |
| Rapid Administration Pilot for Infusing Dinutuximab | NCT05421897 | Neuroblastoma | Dinutuximab wit... | 1 Year - | Children's Hospital Los Angeles | |
| 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | NCT03649438 | Relapsed Neurob... Metastatic Pheo... | 131 I-Metaiodob... Potassium Iodid... G-csf | - | University of Texas Southwestern Medical Center | |
| Parental Decision-Making for Children With Relapsed Neuroblastoma | NCT02282735 | Relapsed Neurob... | 18 Years - | Dana-Farber Cancer Institute | ||
| A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma | NCT01109238 | Refractory Neur... Relapsed Neurob... | 12 Months - 21 Years | Milton S. Hershey Medical Center | ||
| A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma | NCT01109238 | Refractory Neur... Relapsed Neurob... | 12 Months - 21 Years | Milton S. Hershey Medical Center | ||
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | NCT00867568 | Neuroblastoma Medulloblastoma Relapse | TPI 287 | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | NCT03649438 | Relapsed Neurob... Metastatic Pheo... | 131 I-Metaiodob... Potassium Iodid... G-csf | - | University of Texas Southwestern Medical Center | |
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma | NCT05650749 | Refractory Neur... Relapsed Neurob... High-risk Neuro... | GPC2 CAR T cell... | 1 Year - | Children's Hospital of Philadelphia | |
| C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | NCT03635632 | Relapsed Neurob... Refractory Neur... Relapsed Osteos... Relapsed Ewing ... Relapsed Rhabdo... Uveal Melanoma Phyllodes Breas... | C7R-GD2.CART ce... | 1 Year - 74 Years | Baylor College of Medicine | |
| Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | NCT02395666 | Neuroblastoma | DFMO | - 21 Years | Milton S. Hershey Medical Center | |
| Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | NCT01059071 | Neuroblastoma | DFMO Etoposide | - | Milton S. Hershey Medical Center | |
| 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | NCT03649438 | Relapsed Neurob... Metastatic Pheo... | 131 I-Metaiodob... Potassium Iodid... G-csf | - | University of Texas Southwestern Medical Center | |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | NCT04211675 | Relapsed Neurob... Refractory Neur... | Natural Killer ... Temozolomide Irinotecan Dinutuximab Sargramostim | - 29 Years | Nationwide Children's Hospital | |
| Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma | NCT03406273 | Relapsed Neurob... | Cerebral Spinal... Focal radiother... | - 21 Years | Milton S. Hershey Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
